{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:36:48Z","timestamp":1787773008302,"version":"build-2784847793"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.4103\/ijd.ijd_884_22","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T01:47:09Z","timestamp":1715737629000},"page":"234","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Ixekizumab for the Treatment of Acrodermatitis Continua of Hallopeau and Inverse Psoriasis"],"prefix":"10.4103","volume":"68","author":[{"given":"Rui Yuan","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi Yue","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya Mei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Qiang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-32-20240829","first-page":"65","article-title":"Acrodermatitis continua of Hallopeau: Clinical perspectives","volume":"9","author":"Smith","year":"2019","journal-title":"Psoriasis (Auckl"},{"key":"R2-32-20240829","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clindermatol.2015.04.007","article-title":"Psoriasis inversa: A separate identity or a variant of psoriasis vulgaris?","volume":"33","author":"Omland","year":"2015","journal-title":"Clin Dermatol"},{"key":"R3-32-20240829","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/bjd.21701","article-title":"Ixekizumab rapidly improves inflammatory markers in patients with generalized pustular psoriasis","volume":"187","author":"Ito","year":"2022","journal-title":"Br J Dermatol"},{"key":"R4-32-20240829","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1080\/09546634.2019.1620912","article-title":"Treatments for inverse psoriasis: A systematic review","volume":"31","author":"Reynolds","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"R5-32-20240829","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.jsxm.2018.09.004","article-title":"Ixekizumab improved patient-reported genital psoriasis symptoms and impact of symptoms on sexual activity vs placebo in a randomized, double-blind study","volume":"15","author":"Yosipovitch","year":"2018","journal-title":"J Sex Med"},{"key":"R6-32-20240829","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.16736","article-title":"Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis","volume":"179","author":"Ryan","year":"2018","journal-title":"Br J Dermatol"},{"key":"R7-32-20240829","doi-asserted-by":"crossref","first-page":"adv00006","DOI":"10.2340\/00015555-3353","article-title":"Ixekizumab results in persistent clinical improvement in moderate-to-severe genital psoriasis during a 52 week, randomized, placebo-controlled, phase 3 clinical trial","volume":"100","author":"Guenther","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"R8-32-20240829","first-page":"907","article-title":"Ixekizumab for acrodermatitis continua","volume":"16","author":"Pilz","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"R9-32-20240829","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/09546634.2019.1628170","article-title":"Treatment of acrodermatitis continua of hallopeau with ixekizumab","volume":"32","author":"Miller","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"R10-32-20240829","doi-asserted-by":"crossref","first-page":"e15383","DOI":"10.1111\/dth.15383","article-title":"Acrodermatitis continua of hallopeau successfully treated with ixekizumab: A case report","volume":"35","author":"Battista","year":"2022","journal-title":"Dermatol Ther"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_884_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:16:21Z","timestamp":1787771781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_884_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_884_22","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}